Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • mrfox
    Senior Member
    • Aug 2010
    • 103

    varscan2: copynumber detection

    Hi all,

    I would like to know if anybody has experience using VarScan2 to call copynumber (assuming we have Tumor/Normal matched sample). Specifically, I want to know how you calculate the parameter "data ratio".

    Any suggestion will be appreciated.
  • dkoboldt
    Member
    • Mar 2009
    • 62

    #2
    Thank you for your message. We developed VarScan and use it for exome-based copy number analysis. The data-ratio value could simply be calculated by looking at the SAMtools "flagstat" for tumor and normal BAM files to calculate the number of reads that are mapped and unique (not marked duplicate). The ratio should be normal OVER tumor:

    r = (normal_unique_reads / tumor_unique_reads)

    Of course, this assumes that reads are the same length in normal and tumor datasets. If they're not, one would have to adjust for uniquely mapped base pairs.

    You may notice, after calling copy number and performing CBS, some samples with a systematic bias in copy number calls where neutral regions seem shifted away from the zero-axis. We believe these to be instances of different exome capture efficiency between samples.

    You can normalize raw VarScan copy number values up or down to address these situations; see the VarScan copyCaller command usage for details.

    Please feel free to e-mail me directly if you have further questions:
    dkoboldt (at) genome [dot] wustl (dot) edu.

    Comment

    • rpauly
      Member
      • Apr 2011
      • 32

      #3
      I have a question regarding the mergeSegments.pl that is a part of the copy number workflow from Vrascan.

      After a lot of searching, I generated the file with the following columns (Please note, nowhere, on the website is it mentioned that we need the segments.p function from the DNAcopy package to get these columns ):
      ID, chrom, loc.start, loc.end, num.mark, seg.mean, bstat, pval, lcl, ucl.

      and when I try to run this file with mergeSegments.pl ( perl ../../mergeSegments.pl out.file --output-basename basenametest --verbose 1) it gives me an error:

      Use of uninitialized value $input in <HANDLE> at ../../mergeSegments.pl line 446.
      readline() on unopened filehandle at ../../mergeSegments.pl line 446.
      Can't use an undefined value as a symbol reference at ../../mergeSegments.pl line 456.

      What could I change here?

      Comment

      Latest Articles

      Collapse

      • SEQadmin2
        Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
        by SEQadmin2


        Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

        The systematic characterization of the human proteome has
        ...
        07-20-2026, 11:48 AM
      • SEQadmin2
        Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
        by SEQadmin2



        Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
        ...
        07-09-2026, 11:10 AM
      • SEQadmin2
        Cancer Drug Resistance: The Lingering Barrier to Rising Survival
        by SEQadmin2



        Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

        There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
        07-08-2026, 05:17 AM

      ad_right_rmr

      Collapse

      News

      Collapse

      Topics Statistics Last Post
      Started by SEQadmin2, 07-20-2026, 11:10 AM
      0 responses
      12 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-13-2026, 10:26 AM
      0 responses
      30 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-09-2026, 10:04 AM
      0 responses
      41 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-08-2026, 10:08 AM
      0 responses
      26 views
      0 reactions
      Last Post SEQadmin2  
      Working...